BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ramantamig readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Ramantamig\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05652335-3310@assetmemo.bio
DTSTAMP:20261121T004530Z
DTSTART;VALUE=DATE:20270419
DTEND;VALUE=DATE:20270420
SUMMARY:Ramantamig: Phase 1 readout est. (NCT05652335)
DESCRIPTION:Ramantamig\, phase 1\, Multiple Myeloma.\nStudy: A Study of JNJ
 -79635322 in Participants With Relapsed or Refractory Multiple Myeloma or 
 Previously Treated Amyloid Light-chain (AL) Amyloidosis\nEstimated primary
  completion: 19 April 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/ramantamig#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT05652335
URL:https://assetmemo.bio/drug/ramantamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07266441-3310@assetmemo.bio
DTSTAMP:20261121T004530Z
DTSTART;VALUE=DATE:20270614
DTEND;VALUE=DATE:20270615
SUMMARY:Ramantamig: Phase 2 readout est. (NCT07266441)
DESCRIPTION:Ramantamig\, phase 2\, Multiple Myeloma.\nStudy: A Study of JNJ
 -79635322 in Participants With Relapsed or Refractory Multiple Myeloma\nEs
 timated primary completion: 14 June 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/ramantamig#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07266441
URL:https://assetmemo.bio/drug/ramantamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05695508-3310@assetmemo.bio
DTSTAMP:20261121T004530Z
DTSTART;VALUE=DATE:20280915
DTEND;VALUE=DATE:20280916
SUMMARY:Ramantamig: Phase 2 readout est. (NCT05695508)
DESCRIPTION:Ramantamig\, phase 2\, Multiple Myeloma.\nStudy: GMMG-HD10 / DS
 MM-XX / 64007957MMY2003\, MajesTEC-5\nEstimated primary completion: 15 Sep
 tember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ramantam
 ig#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5695508
URL:https://assetmemo.bio/drug/ramantamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07258511-3310@assetmemo.bio
DTSTAMP:20261121T004530Z
DTSTART;VALUE=DATE:20281212
DTEND;VALUE=DATE:20281213
SUMMARY:Ramantamig: Phase 3 readout est. (NCT07258511)
DESCRIPTION:Ramantamig\, phase 3\, Multiple Myeloma.\nStudy: A Study Compar
 ing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecif
 ic Antibody in Participants With Relapsed or Refractory Multiple Myeloma\n
 Estimated primary completion: 12 December 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/ramantamig#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07258511
URL:https://assetmemo.bio/drug/ramantamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06768489-3310@assetmemo.bio
DTSTAMP:20261121T004530Z
DTSTART;VALUE=DATE:20290102
DTEND;VALUE=DATE:20290103
SUMMARY:Ramantamig: Phase 1 readout est. (NCT06768489)
DESCRIPTION:Ramantamig\, phase 1\, Multiple Myeloma.\nStudy: A Study of Ram
 antamig in Combination With Daratumumab With or Without Lenalidomide or of
  Single-agent JNJ-102299639 for Multiple Myeloma\, Newly Diagnosed AL Amyl
 oidosis\, and High-risk Smoldering Multiple Myeloma or Ramantamig in Combi
 nation With Pomalidomide for Multiple Myeloma\nEstimated primary completio
 n: 2 January 2029. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ra
 mantamig#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06768489
URL:https://assetmemo.bio/drug/ramantamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07518186-3310@assetmemo.bio
DTSTAMP:20261121T004530Z
DTSTART;VALUE=DATE:20290429
DTEND;VALUE=DATE:20290430
SUMMARY:Ramantamig: Phase 3 readout est. (NCT07518186)
DESCRIPTION:Ramantamig\, phase 3\, Multiple Myeloma.\nStudy: A Study Compar
 ing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refracto
 ry Multiple Myeloma\nEstimated primary completion: 29 April 2029. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/ramantamig#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07518186
URL:https://assetmemo.bio/drug/ramantamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06500884-3310@assetmemo.bio
DTSTAMP:20261121T004530Z
DTSTART;VALUE=DATE:20300530
DTEND;VALUE=DATE:20300531
SUMMARY:Ramantamig: Phase 2 readout est. (NCT06500884)
DESCRIPTION:Ramantamig\, phase 2\, Multiple Myeloma.\nStudy: A Study to Eva
 luate Preventive Treatments for GPRC5D-related Oral Events\nEstimated prim
 ary completion: 30 May 2030. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/ramantamig#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06500884
URL:https://assetmemo.bio/drug/ramantamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07665450-3310@assetmemo.bio
DTSTAMP:20261121T004530Z
DTSTART;VALUE=DATE:20300904
DTEND;VALUE=DATE:20300905
SUMMARY:Ramantamig: Phase 3 readout est. (NCT07665450)
DESCRIPTION:Ramantamig\, phase 3\, Multiple Myeloma.\nStudy: A Study of Ram
 antamig Plus Daratumumab Versus Daratumumab\, Bortezomib\, Lenalidomide\, 
 and Dexamethasone (DVRd) or Daratumumab\, Lenalidomide\, and Dexamethasone
  (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Plan
 ned\nEstimated primary completion: 4 September 2030. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/ramantamig#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07665450
URL:https://assetmemo.bio/drug/ramantamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07903272-3310@assetmemo.bio
DTSTAMP:20261121T004530Z
DTSTART;VALUE=DATE:20370111
DTEND;VALUE=DATE:20370112
SUMMARY:Ramantamig: Phase 3 readout est. (NCT07903272)
DESCRIPTION:Ramantamig\, phase 3\, Multiple Myeloma.\nStudy: A Trial Compar
 ing Ramantamig and Daratumumab (Ramantamig-D) Versus Daratumumab\, Bortezo
 mib\, Lenalidomide\, and Dexamethasone in Participants With Newly Diagnose
 d Multiple Myeloma Who Are Transplant Eligible\nEstimated primary completi
 on: 11 January 2037. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 ramantamig#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07903272
URL:https://assetmemo.bio/drug/ramantamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
